Cargando…

Large-scale mining disease comorbidity relationships from post-market drug adverse events surveillance data

BACKGROUND: Systems approaches in studying disease relationship have wide applications in biomedical discovery, such as disease mechanism understanding and drug discovery. The FDA Adverse Event Reporting System (FAERS) contains rich information about patient diseases, medications, drug adverse event...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Chunlei, Xu, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309066/ https://www.ncbi.nlm.nih.gov/pubmed/30591027 http://dx.doi.org/10.1186/s12859-018-2468-8

Ejemplares similares

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance
por: Wakabayashi, Tomohito, et al.
Publicado: (2022)

The Alzheimer’s comorbidity phenome: mining from a large patient database and phenome-driven genetics prediction
por: Zheng, Chunlei, et al.
Publicado: (2018)

Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection
por: Xu, Rong, et al.
Publicado: (2014)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

2489. Adverse Events with Biktarvy: Post-Marketing Study
por: Hayes, Edwin, et al.
Publicado: (2019)

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Fusaroli, Michele, et al.
Publicado: (2022)

Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy)
por: Stefanizzi, Pasquale, et al.
Publicado: (2023)

Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records
por: Pan, Yiheng, et al.
Publicado: (2022)

Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance
por: Park, Goeun, et al.
Publicado: (2020)

Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
por: Soldatos, Theodoros G., et al.
Publicado: (2022)

Japanese Physicians’ Views on Drug Post-Marketing Surveillance
por: Maeda, Kazuki, et al.
Publicado: (2015)

Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future
por: Alomar, Muaed, et al.
Publicado: (2020)

Adverse Events of Vaccination against Hepatitis B Virus in Post-Marketing Surveillance from 2005 to 2017 in Guangdong Province, China
por: Liu, Yu, et al.
Publicado: (2022)

Tailoring adverse drug event surveillance to the paediatric inpatient
por: Long, Andrea L, et al.
Publicado: (2010)

Mining drug–target and drug–adverse drug reaction databases to identify target–adverse drug reaction relationships
por: Galletti, Cristiano, et al.
Publicado: (2021)

Efficiently mining Adverse Event Reporting System for multiple drug interactions
por: Xiang, Yang, et al.
Publicado: (2014)

Mining reported adverse events induced by potential opioid-drug interactions
por: Chen, Jinzhao, et al.
Publicado: (2020)

Reporting of adverse events for marketed drugs: Need for strengthening safety database
por: Apte, Aditi Anand
Publicado: (2016)

Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016
por: Mentzer, Dirk, et al.
Publicado: (2018)

Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance
por: Mariottini, Alice, et al.
Publicado: (2022)

Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials
por: Federer, Callie, et al.
Publicado: (2016)

Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance
por: Pop, Gabriela, et al.
Publicado: (2022)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Trust but verify: Is there a role for active surveillance in monitoring adverse events in Zimbabwe’s large-scale male circumcision program?
por: Marongwe, Phiona, et al.
Publicado: (2019)

Mining Patterns of Adverse Events Using Aggregated Clinical Trial Results
por: Luo, Zhihui, et al.
Publicado: (2013)

Predicting potential adverse events using safety data from marketed drugs
por: Daluwatte, Chathuri, et al.
Publicado: (2020)

Early Detection of Adverse Drug Reaction Signals by Association Rule Mining Using Large-Scale Administrative Claims Data
por: Yamamoto, Hiroki, et al.
Publicado: (2023)

Mining Cancer-Specific Disease Comorbidities from a Large Observational Health Database
por: Chen, Yang, et al.
Publicado: (2014)

Adverse Drug Event Ontology: Gap Analysis for Clinical Surveillance Application
por: Adam, Terrence J., et al.
Publicado: (2015)

Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015
por: Moro, Pedro L., et al.
Publicado: (2016)

Post-Marketing Surveillance of Adverse Events Following Vaccination with the Live-Attenuated Japanese Encephalitis Chimeric Virus Vaccine (Imojev(®)) in South Korea, 2015–2019
por: Kim, Hee Soo, et al.
Publicado: (2020)

Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017
por: Stefanizzi, Pasquale, et al.
Publicado: (2020)

Antibacterial‐associated acute kidney injury among older adults: A post‐marketing surveillance study using the FDA adverse events reporting system
por: Chinzowu, Tichawona, et al.
Publicado: (2022)

Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database
por: Altebainawi, Ali F., et al.
Publicado: (2023)

A Pharmacovigilance Approach for Post-Marketing in Japan Using the Japanese Adverse Drug Event Report (JADER) Database and Association Analysis
por: Fujiwara, Masakazu, et al.
Publicado: (2016)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
por: Jiang, Tingting, et al.
Publicado: (2022)

Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov
por: Su, Eric Wen, et al.
Publicado: (2017)

Evaluating Post-Market Adverse Events of The New Hepatitis C Therapies Using FEARS Data
por: Algarni, Majed A.
Publicado: (2022)

A large-scale survey of adverse events experienced in yoga classes
por: Matsushita, Tomoko, et al.
Publicado: (2015)

Adverse Events Following Measles-Mumps-Rubella-Varicella Vaccination and the Case of Seizures: A Post Marketing Active Surveillance in Puglia Italian Region, 2017–2018
por: Stefanizzi, Pasquale, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_von8fqbljvk02v68s30qk5lkkc